Dianosic Closes $7M Funding Round for Chronic Disease Treatment

Dianosic has secured $7,000,000 in investment. This capital injection marks a significant milestone for the company as it advances its mission to address critical challenges in patient adherence to medication through its innovative sustained drug delivery solutions. The company specializes in designing unique sustained intranasal drug delivery solutions for respiratory and chronic central nervous system diseases. Dianosic aims to fight against debilitating chronic diseases that affect millions of people, with an initial focus on chronic allergic rhinitis and chronic rhinosinusitis. These conditions currently see a high percentage of patients non-compliant with treatment and a significant number who do not respond to first-line therapies, profoundly impacting their quality of life. Dianosic closely collaborates with healthcare professionals, including physicians in otorhinolaryngology and neurosurgery, to develop solutions that change physicians' experience and offer patients minimally invasive, non-surgical options. At the core of Dianosic's approach is its ARIS platform, which benefits from proprietary drug-eluting, long-term resorbable polymers. This unique concept is meant to deliver patient-centric, “insert and forget” solutions, maximizing patient quality of life and addressing physicians’ needs in terms of efficacy, safety, ease of use, and patient adherence to treatment. This funding round is crucial for accelerating the development and potential market introduction of these innovative solutions to bridge existing gaps in patient care. Dianosic plans to use the newly secured funds to further advance its research and development initiatives, scale its operational capabilities, and prepare for future regulatory milestones. The investment is expected to support the expansion of its ARIS platform and its ongoing commitment to addressing debilitating chronic diseases. The company is poised to continue its growth trajectory, aiming to become a leading entity in solving medication adherence challenges and improving patient outcomes through its unique drug delivery technology.